Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 4 de 4
Filter
1.
Minerva Ginecol ; 72(1): 12-18, 2020 Feb.
Article in English | MEDLINE | ID: mdl-32153158

ABSTRACT

BACKGROUND: The purpose of the study is to report three years follow-up of single incision slings for the treatment of stress urinary incontinence (SUI). The main outcomes are to evaluate the efficacy of the device and to assess safety, adverse events, quality of life, demographic features of treated women and prognostic factors for SUI. METHODS: We performed a retrospective, double-center, single-arm study. Data were collected by medical records and a telephone interview 3 years after the implant of the mini-sling. Complication rate, subjective efficacy and degree of satisfaction were investigated. RESULTS: Fifty-four patients were treated between March 2015 and March 2017, of which 47 answered the survey. Forty-one of 47 procedures (87.2%) were considered effective. Among more relevant complications, there was one case of extrusion of mesh and three cases of new onset of urinary disfunction, of which two cases of urgency urinary incontinence (UUI) and one case of de-novo SUI. Most complications were solved within few days after the procedure. Concerning the subjective impression of improvement, investigated by using the Patient Global Impression of Improvement (PGI-I) questionnaires, 41 patients reported subjective satisfaction, three reported no change in quality of life and three patients had worsening of symptoms. CONCLUSIONS: The procedure was safe and effective for the treatment of SUI but more data are needed to confirm our preliminary results.


Subject(s)
Suburethral Slings , Urinary Incontinence, Stress/surgery , Female , Follow-Up Studies , Health Surveys/statistics & numerical data , Humans , Middle Aged , Operative Time , Patient Satisfaction , Postoperative Complications/etiology , Quality of Life , Retrospective Studies , Suburethral Slings/adverse effects , Surgical Mesh , Time Factors , Treatment Outcome , Urinary Incontinence, Urge/etiology
2.
Eur Urol Focus ; 4(2): 288-293, 2018 03.
Article in English | MEDLINE | ID: mdl-30205893

ABSTRACT

BACKGROUND: A 11C-choline positron emission tomography/computed tomography (PET/CT) scan is used for restaging prostate cancer (PCa) patients with biochemical recurrence (BCR). Only a few reports have focused on the correlation between PET/CT and nodal relapse location at pathologic examination. OBJECTIVE: To assess the accuracy of PET/CT in predicting the site of nodal relapses in patients undergoing pelvic and/or retroperitoneal salvage lymph node dissection (sLND). DESIGN, SETTING, AND PARTICIPANTS: Multicentric retrospective study including 106 patients with BCR of PCa after radical treatment; all patients but six had a PET/CT showing at least one nodal recurrence and received sLND. OUTCOME MEASUREMENTS AND STATISTICAL ANALYSIS: PET/CT results were compared with histologic findings and analyzed in terms of sensitivity, specificity, and accuracy. Multivariable regression analyses were performed. RESULTS AND LIMITATIONS: Overall sensitivity, specificity, negative and positive predictive value, and accuracy of PET/CT for disease location were 61.6%, 79.3%, 66.3%, 75.7%, and 70.2%, respectively. Sensitivity was 75.5% in the lower pelvis with 69.8% specificity. The retroperitoneal region had high specificity (94.7%) but a relatively low sensitivity (58.3%). The sLNDs did not find any positive nodes in 16 patients (15%). According to regression analyses, discriminative accuracy of PET/CT was 70.4% and improved with an increased number of dissected nodes and prostate-specific antigen doubling time <12 mo. Limitations include retrospective design and lack of a standardized sLND template followed for all patients. CONCLUSIONS: The ability of PET/CT to detect nodal relapses is limited by a high false-positive rate, particularly in the iliac-obturator region and, more alarmingly, a high false-negative rate in the common iliac, sacral, and retroperitoneal regions. An extended template including pelvic and retroperitoneal regions should be adopted when sLND is planned for curative intent. PATIENT SUMMARY: The 11C-choline positron emission tomography/computed tomography scan is a commonly used tool to restage prostate cancer patients with biochemical recurrence, showing an overall per patient accuracy >80%; however, its ability to detect the site of nodal relapses remains suboptimal.


Subject(s)
Carbon Radioisotopes/metabolism , Lymph Node Excision/methods , Neoplasm Recurrence, Local/diagnostic imaging , Positron Emission Tomography Computed Tomography/methods , Prostatic Neoplasms/diagnostic imaging , Salvage Therapy/methods , Aged , Aged, 80 and over , Biomarkers, Tumor/metabolism , Humans , Lymph Nodes/pathology , Lymph Nodes/surgery , Male , Middle Aged , Neoplasm Recurrence, Local/pathology , Neoplasm Recurrence, Local/surgery , Pelvis/diagnostic imaging , Pelvis/pathology , Predictive Value of Tests , Prostate-Specific Antigen , Prostatic Neoplasms/blood , Prostatic Neoplasms/pathology , Prostatic Neoplasms/surgery , Retroperitoneal Space/diagnostic imaging , Retroperitoneal Space/pathology , Retroperitoneal Space/surgery , Retrospective Studies
4.
Urologia ; 79(2): 152-5, 2012.
Article in Italian | MEDLINE | ID: mdl-22610842

ABSTRACT

The functional relationship between parathyroid glands and prostatic gland is commonly very well known. The aim of our study was to investigate the relationship between serum levels of PTH and serum levels of PSA in patients with pathological finding of BPH. According to 261 transrectal ultrasound-guided prostatic biopsies performed from March 2009 to March 2010, 75 patients, responding to our inclusion criteria, were selected. 26 patients (34.6%) ended the study. All patients with high serum levels of PSA (>4 ng/mL), with histological diagnosis of benign prostatic hyperplasia, underwent the assay of serum levels of PTH. We observed high levels of PTH (> 66 pg/mL) in 9 patients (35.2%).


Subject(s)
Parathyroid Hormone/blood , Prostate-Specific Antigen/blood , Prostatic Hyperplasia/blood , Aged , Aged, 80 and over , Aging/metabolism , Biopsy , Calcifediol/metabolism , Humans , Male , Middle Aged , Prostate/pathology , Prostatic Hyperplasia/pathology
SELECTION OF CITATIONS
SEARCH DETAIL
...